Results 201 to 210 of about 47,373 (236)

Aripiprazole for the treatment of Tourette syndrome

Expert Review of Neurotherapeutics, 2021
Introduction: Tourette syndrome (TS) is a neurodevelopmental disorder characterized by multiple tics which often persisting in forms of different severity throughout adult life. The prevalence of neuropsychiatric co-morbidity in patients with TS is high.
J. H. Cox, A. Cavanna
semanticscholar   +1 more source

Aripiprazole

Expert Opinion on Pharmacotherapy, 2005
Aripiprazole is a new chemical entity with a unique pharmacological profile. It has strong affinities for certain dopamine receptors, and intermediate affinity for serotonin, adrenergic and histamine receptors. Partial agonism of the D2 dopamine and 5HT1A serotonin receptors, and antagonism of the 5HT2 serotonin receptor are believed to be the ...
openaire   +3 more sources

Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial.

Psychopharmacology bulletin
The objective of the study was to assess the efficacy and safety of aripiprazole in outpatients with posttraumatic stress disorder (PTSD) on a 12-week, open-label trial.
G. Villarreal, L. Calais, J. Cañive, S. L. Lundy, J. Pickard, G. Toney   +5 more
semanticscholar   +1 more source

An open-label assessment of aripiprazole in the treatment of PTSD.

Psychopharmacology bulletin
BACKGROUND Recent studies suggest that atypical antipsychotics may be effective augmentation strategies for the treatment of posttraumatic stress disorder (PTSD).
S. Robert, M. Hamner, V. Durkalski, Mary W. Brown, H. Ulmer   +4 more
semanticscholar   +1 more source

Aripiprazole in Children and Adolescents

Journal of child and adolescent psychopharmacology, 2020
Objective: To review the use of aripiprazole in children and adolescents. Methods: Medline and Embase databases were systematically searched using the keywords aripiprazole and child or adolescent over the period from 2000 to 2019.
Nicolas Coustals, Marie-Line Ménard, D. Cohen   +2 more
semanticscholar   +1 more source

Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.

Journal of Clinical Psychiatry, 2019
OBJECTIVE To report the symptomatic and functional outcomes in patients with major depressive disorder (MDD) during a 2-phase treatment trial and to estimate the value of early improvement after 2 weeks in predicting clinical response to escitalopram and
S. Kennedy, R. Lam, S. Rotzinger, R. Milev, P. Blier, J. Downar, K. Evans, F. Farzan, J. Foster, B. Frey, P. Giacobbe, G. Hall, K. Harkness, S. Hassel, Z. Ismail, F. Leri, S. McInerney, G. MacQueen, L. Minuzzi, D. Müller, S. Parikh, F. Placenza, Lena C. Quilty, A. Ravindran, R. Sassi, C. Soares, S. Strother, G. Turecki, A. Vaccarino, F. Vila-Rodriguez, Joanna Yu, R. Uher   +31 more
semanticscholar   +1 more source

Application of the Method of Molecular Voronoi–Dirichlet Polyhedra for Analysis of Noncovalent Interactions in Aripiprazole Polymorphs

, 2020
Aripiprazole (APZ) is a highly polymorphic chemical compound with nine structurally characterized modifications.
V. N. Serezhkin, A. Savchenkov
semanticscholar   +1 more source

Aripiprazole: An FDA Approved Bioactive Compound to treat schizophrenia-A Mini Review.

Current Drug Discovery Technologies, 2020
OBJECTIVE Aripiprazole,a synthetic compound, obtained by chemical modification of the structure of quinolinone is considered as an atypical antipsychotic drug.
Arvind Kumar, Harpreet Singh, A. Mishra, A. Mishra   +3 more
semanticscholar   +1 more source

Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media

BMJ evidence-based medicine, 2019
Background In November 2017, the Food and Drug Administration (FDA) approved a version of a second-generation antipsychotic, aripiprazole, embedded with a sensor (Abilify MyCite).
Lisa Cosgrove, I. Cristea, A. Shaughnessy, B. Mintzes, F. Naudet   +4 more
semanticscholar   +1 more source

An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes

Journal of Psychopharmacology, 2019
Purpose: This study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (FES).
Zhang Cheng, Yan-bo Yuan, Xue Han, Lei Yang, S. Cai, Fude Yang, Zheng Lu, Chuanyue Wang, H. Deng, Jingping Zhao, Y. Xiang, C. Correll, Xin Yu   +12 more
semanticscholar   +1 more source